medigraphic.com

2004, Number S1

<< Back Next >>

Rev Mex Anest 2004; 27 (S1)

Prevention and management of bleeding

Levy JH

Language: English
References: 13
Page: 52-53
PDF size: 54.95 Kb.


Text Extraction

INTRODUCTION

Major components of the hemostasis include the vasculature, platelets, and coagulation proteins. Any deficiencies or abnormality in any of these integral components will lead to pathologic bleeding and postoperative coagulopathy. Multiple aspects of cardiac surgery, either on or off pump procedures can produce bleeding. This discussion will review concepts in the prevention and management of coagulopathies primarily in cardiac surgical patients.


REFERENCES

  1. Alderman EL, Levy JH, Rich J, et al. International multi-center aprotinin graft patency experience (IMAGE). J Thorac Cardiovasc Surg 1998;116:716-730.

  2. Despotis GJ, Filos K, Gravlee G, Levy J. Anticoagulation monitoring during cardiac surgery: a survey of current practice and review of current and emerging techniques. Anesthesiology 1999;91:1122-1151.

  3. Despotis GJ. Skubas NJ. Goodnough LT. Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Seminars in Thoracic & Cardiovascular Surgery. 1999;11(2):84-104.

  4. Hedner U. Recombinant coagulation factor VIIa: From the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000;26:363.

  5. Levy JH, Goodnough LT, Grelich P, et al. A room temperature stable hemoglobin (HBOC-201) eliminates allogeneic red blood cell transfusion in postoperative cardiac surgery patients. J Thorac Cardiovasc Surg 2002;124:35-42.

  6. Levy JH, Pifarre R, Schaff H, et al. A multicenter, placebo-controlled, double-blind trial of aprotinin to reduce blood loss and the requirement of donor blood transfusion in patients undergoing repeat CABG. Circulation 1995;92:2236-2244.

  7. Levy JH. Hemostatic agents and their safety. J Cardioth Anesth 1999;13(S1):6-11.

  8. Levy JH. Novel intravenous antithrombins. American Heart Journal (Suppl), Am Heart J 2001;141:1043-1047.

  9. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001;72:S1814-1820.

  10. Levy JH: Novel pharmacologic approaches to reduce bleeding. Can J Anaesth 2003;50(6 Suppl):S26-30.

  11. Miller BE, Tosone SR, Tam VKH, et al. Hematologic and economic impact of aprotinin in reop pediatric cardiac surgery. Ann Thorac Surg 1998;66:535-540.

  12. Mojcik C, Levy JH. Systemic inflammatory response syndrome and anti-inflammatory strategies. Ann Thorac Surg 2001;71:745-754.

  13. Tanaka KA, Waly A, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah’s Witness patients after cardiac surgery with recombinant activated Factor VII (NovoSeven®). Anesthesiology 2003;98:1513-5.




2020     |     www.medigraphic.com